Romosozumab was not associated with increased cardiovascular risks among patients with osteoporosis when compared with bisphosphonate use. Romosozumab does not appear to significantly increase the ...

Data from the FRAME study showed romosozumab significantly reduced ... But the drug, which helps rebuild bone by targeting the enzyme sclerostin, missed a secondary endpoint of reducing non ...

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD among postmenopausal women with T2D and osteoporosis. Romosozumab followed by alendronate treatment ...